1. Home
  2. CERO vs GTBP Comparison

CERO vs GTBP Comparison

Compare CERO & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • GTBP
  • Stock Information
  • Founded
  • CERO 2017
  • GTBP 1965
  • Country
  • CERO United States
  • GTBP United States
  • Employees
  • CERO N/A
  • GTBP N/A
  • Industry
  • CERO
  • GTBP Biotechnology: Pharmaceutical Preparations
  • Sector
  • CERO
  • GTBP Health Care
  • Exchange
  • CERO Nasdaq
  • GTBP Nasdaq
  • Market Cap
  • CERO 8.4M
  • GTBP 4.9M
  • IPO Year
  • CERO N/A
  • GTBP N/A
  • Fundamental
  • Price
  • CERO $1.84
  • GTBP $2.16
  • Analyst Decision
  • CERO
  • GTBP Strong Buy
  • Analyst Count
  • CERO 0
  • GTBP 1
  • Target Price
  • CERO N/A
  • GTBP $11.00
  • AVG Volume (30 Days)
  • CERO 742.5K
  • GTBP 39.6K
  • Earning Date
  • CERO 02-24-2025
  • GTBP 03-25-2025
  • Dividend Yield
  • CERO N/A
  • GTBP N/A
  • EPS Growth
  • CERO N/A
  • GTBP N/A
  • EPS
  • CERO N/A
  • GTBP N/A
  • Revenue
  • CERO N/A
  • GTBP N/A
  • Revenue This Year
  • CERO N/A
  • GTBP N/A
  • Revenue Next Year
  • CERO N/A
  • GTBP N/A
  • P/E Ratio
  • CERO N/A
  • GTBP N/A
  • Revenue Growth
  • CERO N/A
  • GTBP N/A
  • 52 Week Low
  • CERO $1.70
  • GTBP $1.72
  • 52 Week High
  • CERO $1,238.00
  • GTBP $10.66
  • Technical
  • Relative Strength Index (RSI)
  • CERO 33.43
  • GTBP 48.88
  • Support Level
  • CERO $1.70
  • GTBP $2.03
  • Resistance Level
  • CERO $2.22
  • GTBP $2.38
  • Average True Range (ATR)
  • CERO 0.28
  • GTBP 0.18
  • MACD
  • CERO 0.25
  • GTBP 0.02
  • Stochastic Oscillator
  • CERO 9.46
  • GTBP 73.68

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: